FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4320490838> ?p ?o ?g. }

• W4320490838 endingPage "967" @default.
• W4320490838 startingPage "957" @default.
• W4320490838 abstract "Background: Lesions of the articular cartilage, with or without involvement of the subchondral bone, are a common cause of pain and dysfunction in the knee. Although several treatment options have been developed, the majority of previous clinical trials examined patients with isolated or focal midsized defects, which rarely represent the condition found in the general population. Rather, cartilage lesions are often associated with the presence of mild to moderate osteoarthritic changes. Purpose: The present multicenter randomized controlled trial compared the clinical and radiographic outcomes of an aragonite-based osteochondral implant with a control group (arthroscopic debridement/microfractures) in patients affected by joint surface lesions of the knee, including those with concurrent mild to moderate osteoarthritis. Study Design: Randomized controlled trial; Level of evidence, 1. Methods: A total of 251 patients were enrolled in 26 medical centers according to the following criteria: age 21 to 75 years, up to 3 cartilage defects of International Cartilage Regeneration & Joint Preservation Society grade 3a or above located on the femoral condyles and/or trochlea, total treatable area from 1 to 7 cm 2 , bony defect depth ≤8 mm, and knee osteoarthritis grade 0 to 3 according to Kellgren-Lawrence score. Patients were randomized to the aragonite-based implant or debridement/microfracture control arm in a 2:1 ratio. Evaluation was performed at 6, 12, 18, and 24 months based on overall Knee injury and Osteoarthritis Outcome Score (KOOS) as the primary endpoint, and the KOOS subscales (Pain, Quality of Life, Activities of Daily Living), percentage of responders, and International Knee Documentation Committee (IKDC) subjective score as the secondary endpoints. Patients also underwent magnetic resonance imaging evaluation at 12 and 24 months to assess defect fill grade. Failures (ie, need for any secondary treatment) and adverse events were also recorded. Results: The implant group showed a statistically superior outcome in the primary endpoint and all secondary endpoints at each follow-up. The magnitude of improvement in the implant group was twice as large as that in the control group in terms of mean KOOS improvement at 2 years. Responder rate (defined as at least a 30-point improvement in overall KOOS) was 77.8% in the implant group as opposed to 33.6% in the control ( P < .0001). Statistically superior results were seen in the IKDC score as well. At 24 months, 88.5% of the implanted group had at least 75% defect fill on magnetic resonance imaging as compared with 30.9% of controls ( P < .0001). The failure rate was 7.2% for the implant group versus 21.4% for control. Conclusion: This aragonite-based scaffold was safe and effective in the treatment of chondral and osteochondral lesions in the knee, including patients with mild to moderate osteoarthritis, and provided superior outcomes as compared with the control group. Registration: NCT03299959 (ClinicalTrials.gov identifier)." @default.
• W4320490838 created "2023-02-14" @default.
• W4320490838 creator A5005052927 @default.
• W4320490838 creator A5011885824 @default.
• W4320490838 creator A5015853377 @default.
• W4320490838 creator A5022326090 @default.
• W4320490838 creator A5047339498 @default.
• W4320490838 creator A5049942811 @default.
• W4320490838 creator A5056332780 @default.
• W4320490838 creator A5075282062 @default.
• W4320490838 creator A5076124631 @default.
• W4320490838 creator A5083730539 @default.
• W4320490838 creator A5087722284 @default.
• W4320490838 creator A5091296325 @default.
• W4320490838 date "2023-02-13" @default.
• W4320490838 modified "2023-10-18" @default.
• W4320490838 title "Aragonite-Based Scaffold Versus Microfracture and Debridement for the Treatment of Knee Chondral and Osteochondral Lesions: Results of a Multicenter Randomized Controlled Trial" @default.
• W4320490838 cites W1716794597 @default.
• W4320490838 cites W1907180716 @default.
• W4320490838 cites W1987547674 @default.
• W4320490838 cites W2006814451 @default.
• W4320490838 cites W2013768928 @default.
• W4320490838 cites W2014361907 @default.
• W4320490838 cites W2061037596 @default.
• W4320490838 cites W2068642220 @default.
• W4320490838 cites W2080948384 @default.
• W4320490838 cites W2088564623 @default.
• W4320490838 cites W2105596400 @default.
• W4320490838 cites W2111250044 @default.
• W4320490838 cites W2129573593 @default.
• W4320490838 cites W2137368902 @default.
• W4320490838 cites W2139861324 @default.
• W4320490838 cites W2146224425 @default.
• W4320490838 cites W2171641639 @default.
• W4320490838 cites W2189356424 @default.
• W4320490838 cites W2226958754 @default.
• W4320490838 cites W2334736834 @default.
• W4320490838 cites W2511057511 @default.
• W4320490838 cites W2606607285 @default.
• W4320490838 cites W2754497356 @default.
• W4320490838 cites W2793875518 @default.
• W4320490838 cites W2898786773 @default.
• W4320490838 cites W2899101847 @default.
• W4320490838 cites W2946446291 @default.
• W4320490838 cites W2951271058 @default.
• W4320490838 cites W2965017613 @default.
• W4320490838 cites W2986503922 @default.
• W4320490838 cites W3007020926 @default.
• W4320490838 cites W3097651231 @default.
• W4320490838 cites W3121697539 @default.
• W4320490838 cites W3139020909 @default.
• W4320490838 cites W3195598718 @default.
• W4320490838 doi "https://doi.org/10.1177/03635465231151252" @default.
• W4320490838 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36779614" @default.
• W4320490838 hasPublicationYear "2023" @default.
• W4320490838 type Work @default.
• W4320490838 citedByCount "3" @default.
• W4320490838 countsByYear W43204908382023 @default.
• W4320490838 crossrefType "journal-article" @default.
• W4320490838 hasAuthorship W4320490838A5005052927 @default.
• W4320490838 hasAuthorship W4320490838A5011885824 @default.
• W4320490838 hasAuthorship W4320490838A5015853377 @default.
• W4320490838 hasAuthorship W4320490838A5022326090 @default.
• W4320490838 hasAuthorship W4320490838A5047339498 @default.
• W4320490838 hasAuthorship W4320490838A5049942811 @default.
• W4320490838 hasAuthorship W4320490838A5056332780 @default.
• W4320490838 hasAuthorship W4320490838A5075282062 @default.
• W4320490838 hasAuthorship W4320490838A5076124631 @default.
• W4320490838 hasAuthorship W4320490838A5083730539 @default.
• W4320490838 hasAuthorship W4320490838A5087722284 @default.
• W4320490838 hasAuthorship W4320490838A5091296325 @default.
• W4320490838 hasConcept C141071460 @default.
• W4320490838 hasConcept C142724271 @default.
• W4320490838 hasConcept C168563851 @default.
• W4320490838 hasConcept C203092338 @default.
• W4320490838 hasConcept C204787440 @default.
• W4320490838 hasConcept C2776164576 @default.
• W4320490838 hasConcept C2777438270 @default.
• W4320490838 hasConcept C2781411149 @default.
• W4320490838 hasConcept C2908647359 @default.
• W4320490838 hasConcept C2908736133 @default.
• W4320490838 hasConcept C71924100 @default.
• W4320490838 hasConcept C99454951 @default.
• W4320490838 hasConceptScore W4320490838C141071460 @default.
• W4320490838 hasConceptScore W4320490838C142724271 @default.
• W4320490838 hasConceptScore W4320490838C168563851 @default.
• W4320490838 hasConceptScore W4320490838C203092338 @default.
• W4320490838 hasConceptScore W4320490838C204787440 @default.
• W4320490838 hasConceptScore W4320490838C2776164576 @default.
• W4320490838 hasConceptScore W4320490838C2777438270 @default.
• W4320490838 hasConceptScore W4320490838C2781411149 @default.
• W4320490838 hasConceptScore W4320490838C2908647359 @default.
• W4320490838 hasConceptScore W4320490838C2908736133 @default.
• W4320490838 hasConceptScore W4320490838C71924100 @default.
• W4320490838 hasConceptScore W4320490838C99454951 @default.
• W4320490838 hasIssue "4" @default.
• W4320490838 hasLocation W43204908381 @default.
• W4320490838 hasLocation W43204908382 @default.

• next